Lung disease caused by
Mycobacterium abscessus
is very difficult to cure, and treatment failure rates are high. The antituberculosis drug bedaquiline (BDQ) is used as salvage therapy against this dreadful disease. However, BDQ is highly lipophilic, displays a long terminal half-life, and presents a cardiotoxicity liability associated with QT interval prolongation. Recent medicinal chemistry campaigns resulted in the discovery of 3,5-dialkoxypyridine analogues of BDQ which are less lipophilic, have higher clearance, and display lower cardiotoxic potential.
脓肿分枝杆菌引起的肺病
脓肿分枝杆菌
很难治愈,治疗失败率很高。抗结核药物贝达喹啉(BDQ)被用作这种可怕疾病的挽救疗法。然而,贝达喹啉亲脂性强,半衰期长,并具有与 QT 间期延长相关的心脏毒性。最近的药物化学研究发现了 3,5-二烷氧基吡啶的 BDQ 类似物,其亲脂性较低,清除率较高,心脏毒性较低。